About me
Dr. Liang Schweizer is the Founder, Chairperson and CEO of HiFiBiO Therapeutics, a clinical stage biotech company with deep expertise in immune modulation and a proprietary translational platform Drug Intelligence Science (DIS®). Under her leadership, HiFiBiO Therapeutics successfully discovered 8 clinical candidates, with three currently in Phase I. The company was named a “Fierce 15” Biotech Company in 2023, and its DIS® platform was recognized as an “AI Innovation of the Year” by Breakthrough Biotech.
Previously, Dr. Schweizer co-founded Harbour Biomed as its CSO and successfully transformed the antibody platform company into a drug discovery and development enterprise. Before launching her entrepreneurial career, Dr. Schweizer served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline and contributing across global oncology programs from preclinical to clinical stages. Prior to Sanofi, she progressed her career from an oncology drug discovery project leader to director in Leads Discovery and Optimization at Bristol-Myers Squibb Company.
Dr. Schweizer is well recognized for her long-term vision, open innovation strategy, and business acumen, securing more than $230 million in private financing and over $80M in non-dilutive funding throughout her career. Her entrepreneurial spirit, commitment to purpose, and impact led to her recognition as an EY Entrepreneur Of The Year® 2024 New England Award Winner. Additionally, she has been named one of the world’s top female founders by Business Financing, UK, and recognized with an Extraordinary Women Advancing Healthcare Award by The Commonwealth Institute of Massachusetts. In total, she has significantly contributed to 5 marketed drugs and over 30 clinical candidates. She is also the co-inventor of over 12 immunomodulatory therapeutic antibodies and more than 50 patent publications.
Dr. Schweizer graduated from the University of Science and Technology of China (USTC), majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with a Minor in Chemical Engineering. Liang earned her Ph.D in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York. Recently, she completed the Program for Leadership Development at Harvard Business School.